Shaping the Future

of Mitral Valve Replacement

Our Technology

THE TIOGA TMVR SYSTEM

  • Unique valve and anchor design
  • Designed to minimize patient exclusions and treat more patients with MR

The Tioga TMVR System is for Investigational Use only and is not for sale in the U.S. or outside the U.S.

  • Large atrial brim designed to reduce 
paravalvular leak risk
  • Reduced valve height designed to reduce risk 
of left ventricular outflow tract obstruction
  • Atrial brim accommodates both small and large native mitral valve sizes
  • Gently encircles and captures chordae to bring mitral valve leaflets together
  • Can be repositioned and redeployed, as needed, prior to release
  • Fits waist of valve as it expands
Valve
  • Large atrial brim designed to reduce 
paravalvular leak risk
  • Reduced valve height designed to reduce risk 
of left ventricular outflow tract obstruction
  • Atrial brim accommodates both small and large native mitral valve sizes
Anchor
  • Gently encircles and captures chordae to bring mitral valve leaflets together
  • Can be repositioned and redeployed, as needed, prior to release
  • Fits waist of valve as it expands

LOW-PROFILE DELIVERY SYSTEMS Intended FOR PROCEDURAL EASE

Anchor Delivery System

28 French delivery system with deflectable/ steerable catheters

Valve Delivery System

28 French over-the-wire delivery system with steerability and depth control

See How It Works

Clinical Need

Mitral Regurgitation (or MR) is the most common heart valve condition, impacting more than 6.6 million people.1 MR occurs when the leaflets of the mitral valve do not close properly, which results in blood flowing backward or “leaking” from the left ventricle into the left atrium.

For patients with MR, the heart compensates and works harder to ensure that enough blood flows properly to the body.

Over time, as MR becomes more severe, the increased workload can lead to cardiac symptoms and complications, such as:

  • Stroke
  • Heart failure
  • Pulmonary hypertension
  • Death

1. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958-1966.; US Census Data

1. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958-1966.; US Census Data

Mitral Regurgitation (or MR) is the most common heart valve condition, impacting more than 6.6 million people.1 MR occurs when the leaflets of the mitral valve do not close properly, which results in blood flowing backward or “leaking” from the left ventricle into the left atrium.

For patients with MR, the heart compensates and works harder to ensure that enough blood flows properly to the body.

Over time, as MR becomes more severe, the increased workload can lead to cardiac symptoms and complications, such as:

  • Stroke
  • Heart failure
  • Pulmonary hypertension
  • Death

1. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958-1966.; US Census Data

1. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958-1966.; US Census Data

Medical

Medical treatment targeted at preservation / improvement of heart muscle function

Surgical

Surgery to repair or replace the mitral valve

  • Repair: primarily mitral annuloplasty
  • Replacement: done infrequently because of invasiveness and fragile nature of patients

Transcatheter

  • Transcatheter edge-to-edge (TEER) repair is the only commercially-available therapy but not every patient is a candidate for TEER
  • TMVR options are in early stages of clinical evaluation and investigation

Mayo Clinic, Mitral Valve Regurgitation Overview. September 2023.

News